From: Impact of sex and gender on COVID-19 outcomes in Europe
Virus | Antiviral drug/vaccine | Sex-specific features | Comments | References |
---|---|---|---|---|
HIV | HAART | M < F | CD4+ T cell count, adverse reactions, fat accumulation, drug concentration, virus clearance, hepatitis | |
 | HAART | M > F | Fat loss, survival | |
HSV-2 | HSV-2 gD vaccine | M < F | Humoral immune responses, cell-mediated immune responses, vaccine efficacy | |
 | Acyclovir | M < F | Frequency of prescription, adverse reaction | |
 | Acyclovir | M > F | Reduction of virus shedding | [114] |
HBV | HBV vaccine | M < F | Humoral immune responses | |
HCV | Pegylated interferon alpha/ribavirin | M < F | Adverse reaction, sustained virologic response1 | |
Seasonal influenza viruses | TIV vaccine | M < F | Humoral immune responses, adverse reactions | |
 | Oseltamivir | M < F | Drug clearance and metabolism2 | [126] |
 | Oseltamivir | M > F | Alleviation of symptoms, reduction of viral load | [127] |
 | Zanamivir | M = F | Alleviation of symptoms, reduction of viral load | [127] |